

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1950-2008/Feb 22

(c) format only 2008 Dialog

*File 155: MEDLINE has reloaded. Please see HELP NEWS 155 for details.

File 5:Biosis Previews(R) 1926-2008/Feb W4

(c) 2008 The Thomson Corporation

File 34:SciSearch(R) Cited Ref Sci 1990-2008/Mar W1

(c) 2008 The Thomson Corp

File 35:Dissertation Abs Online 1861-2008/Nov

(c) 2008 ProQuest Info&Learning

File 45:EMCare 2008/Feb W4

(c) 2008 Elsevier B.V.

File 65:Inside Conferences 1993-2008/Feb 29

(c) 2008 BLDSC all rts. reserv.

File 71:ELSEVIER BIOBASE 1994-2008/Feb W4

(c) 2008 Elsevier B.V.

File 73:EMBASE 1974-2008/Mar 04

(c) 2008 Elsevier B.V.

*File 73: The 2008 EMTREE Thesaurus has been loaded. Please see HELP NEWS 72 for details.

File 91:MANTIS(TM) 1880-2007/Apr

2001 (c) Action Potential

*File 91: This database has stopped updating temporarily. Please see HELP NEWS 91 for details.

File 98:General Sci Abs 1984-2008/Mar

(c) 2008 The HW Wilson Co.

File 135:NewsRx Weekly Reports 1995-2008/Mar W1

(c) 2008 NewsRx

File 144:Pascal 1973-2008/Mar W1

(c) 2008 INIST/CNRS

File 149:TGG Health&Wellness DB(SM) 1976-2008/Feb W2

(c) 2008 The Gale Group

File 156:ToxFile 1965-2008/Feb W3

(c) format only 2008 Dialog

*File 156: ToxFile has resumed updating with the 2008 MeSH. Please see HELP NEWS154 for information.

File 159:Cancerlit 1975-2002/Oct

(c) format only 2002 Dialog

File 162:Global Health 1983-2008/Dec

(c) 2008 CAB International

File 164:Allied & Complementary Medicine 1984-2008/Feb

(c) 2008 BLHCIS

File 172:EMBASE Alert 2008/Feb 08

(c) 2008 Elsevier B.V.

File 266:FEDRIP 2007/Nov

Comp & dist by NTIS, Intl Copyright All Rights Res

File 369:New Scientist 1994-2007/Sep W4

(c) 2007 Reed Business Information Ltd.

File 370:Science 1996-1999/Jul W3

(c) 1999 AAAS

*File 370: This file is closed (no updates). Use File 47 for more current information.

File 399:CA SEARCH(R) 1967-2007/UD=14810

(c) 2008 American Chemical Society

*File 399: Use is subject to the terms of your user/customer agreement. IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.

File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec

(c) 2006 The Thomson Corp

File 444:New England Journal of Med. 1985-2008/Jan W1

(c) 2008 Mass. Med. Soc.

Set	Items	Description
---	-----	-----

? e bedsores

Ref	Items	Index-term
E1	1	BEDSORE TREATMENT
E2	1	BEDSORE-PREVENTING SHEET
E3	1543	*BEDSORES
E4	8	BEDSORES DECUBITUS ULCER
E5	1	BEDSORES-PREVENTION
E6	1	BEDSORES-TREATMENT
E7	2	BEDSORESOLUTIONS
E8	2	BEDSORIOSES
E9	1	BEDSOSIAN
E10	1	BEDSOW
E11	39	BEDSPACE
E12	1	BEDSPACE CONTAMINATION

Enter P or PAGE for more

? s e3:e7

S1	1545	'BEDSORES': 'BEDSORESOLUTIONS'
----	------	--------------------------------

? e bed sore

Ref	Items	RT	Index-term
E1	1		BEDSONS
E2	1		BEDSORBENT
E3	433	4	*BEDSORE
E4	1		BEDSORE CLASSIFICATION
E5	1		BEDSORE MAIN-FACTOR MEASURING DEVICE
E6	1		BEDSORE OCCURRENCE
E7	1		BEDSORE PREVENTION APPARATUS
E8	1		BEDSORE PREVENTION-TREATMENT
E9	1		BEDSORE TREATMENT
E10	1		BEDSORE-PREVENTING SHEET
E11	1543		BEDSORES
E12	8		BEDSORES DECUBITUS ULCER

Enter P or PAGE for more

? se3:e11

S2	1848	'BEDSORE': 'BEDSORES'
----	------	-----------------------

? e e3

Ref	Items	Type	RT	Index-term
R1	132		4	*BEDSORE
R2	10081	U	32	DECUBITUS
R3	7541	X	10	PRESSURE ULCER

? s r1:r3

S3	17640	R1:R3
----	-------	-------

? e r2

Ref	Items	Type	RT	Index-term
R1	10081		32	*DECUBITUS
R2	5681	B	34	SKIN INJURY
R3	7332	B	46	SKIN ULCER
R4	0	S	2	BED SORE
R5	86	S	2	BEDSORE
R6	0	S	2	DECUBITAL ULCER
R7	0	S	2	DECUBITAL ULCUS

R8	0	S	2	DECUBITUS ULCER
R9	0	S	2	DECUBITUS ULCERATION
R10	0	S	2	DECUBITUS ULCERS
R11	0	S	2	DECUBITUS ULCUS
R12	0	S	2	DECUBUS ULCER

Enter P or PAGE for more

? p

Ref	Items	Type	RT	Index-term
R13	0	S	2	PRESSURE SORE
R14	0	S	2	PRESSURE ULCER
R15	0	S	2	SORE,PRESSURE
R16	0	S	2	ULCER,PRESSURE
R17	0	S	2	ULCUS DECUBITUS

? p

>>>Related terms display completed...

? s r1:r3

S4 22428 R1:R3

? ds

Set	Items	Description
S1	1545	'BEDSORES': 'BEDSORESOLUTIONS'
S2	1848	'BEDSORE': 'BEDSORES'
S3	17640	R1:R3
S4	22428	R1:R3

? s s1 or s2 or s3 or s4

1545	S1
1848	S2
17640	S3
22428	S4
S5	31395 S1 OR S2 OR S3 OR S4

? e botox

Ref	Items	RT	Index-term
E1	1		BOTOWANA
E2	2		BOTOWSPHAERIA
E3	8658	2	*BOTOX
E4	1		BOTOX (ALLERGAN INC IRVINE, CA)
E5	13		BOTOX (R)
E6	64	2	BOTOX A
E7	5		BOTOX ALLERGAN
E8	1		BOTOX ANTIBODIES
E9	1		BOTOX BOTULIC TOXIN A
E10	1		BOTOX BOTULININ TOXIN TYPE A
E11	1		BOTOX BOTULINUM A TOXIN
E12	5		BOTOX BOTULINUM TOXIN

Enter P or PAGE for more

? s e3:e12

S6 8658 'BOTOX': 'BOTOX BOTULINUM TOXIN'

? p

Ref	Items	RT	Index-term
E13	3		BOTOX BOTULINUM TOXIN A
E14	7		BOTOX BOTULINUM TOXIN TYPE A
E15	1		BOTOX BOTULINUM TYPE A TOXIN
E16	27	2	BOTOX COSMETIC
E17	1		BOTOX FALSE VOCAL FOLDS
E18	3		BOTOX INJECTION
E19	1		BOTOX INJECTION NEEDLE

E20	1	BOTOX INJECTIONS
E21	1	BOTOX STRAIN
E22	2	BOTOX THERAPY
E23	4	BOTOX TREATMENT
E24	1	BOTOX TYPE A BOTULINUM TOXIN

Enter P or PAGE for more

```
? s e13:e15
      S7      11  'BOTOX BOTULINUM TOXIN A': 'BOTOX BOTULINUM TYPE A TOXIN'
? e botulinum toxin
```

Ref	Items	RT	Index-term
E1	1		BOTULINUM TOXI
E2	2		BOTULINUM TOXICITY
E3	12250	18	*BOTULINUM TOXIN
E4	1		BOTULINUM TOXIN (BOTOX)
E5	4		BOTULINUM TOXIN (BOTX)
E6	1		BOTULINUM TOXIN (THERAPEUTIC USE)
E7	551		BOTULINUM TOXIN --ADVERSE DRUG REACTION --AE
E8	374		BOTULINUM TOXIN --CLINICAL TRIAL --CT
E9	210		BOTULINUM TOXIN --DRUG ADMINISTRATION --AD
E10	23		BOTULINUM TOXIN --DRUG ANALYSIS --AN
E11	51		BOTULINUM TOXIN --DRUG COMBINATION --CB
E12	108		BOTULINUM TOXIN --DRUG COMPARISON --CM

Enter P or PAGE for more

```
? s e3:e12
      S8      12255  'BOTULINUM TOXIN': 'BOTULINUM TOXIN --DRUG COMPARISON
                        --CM'
? e e3
```

Ref	Items	Type	RT	Index-term
R1	7225		18	*BOTULINUM TOXIN
R2	5351	B	142	BACTERIAL TOXIN
R3	0	S	2	BOTULINAL TOXIN TEST
R4	0	S	2	BOTULINIUM TOXIN
R5	0	S	2	BOTULINUM NEUROTOXIN
R6	0	S	2	BOTULINUM TOXINS
R7	0	S	2	BOTULINUS TOXIN
R8	0	S	2	BOTULISM TOXIN
R9	0	S	2	CLOSTRIDIUM BOTULINUM EXOTOXIN
R10	0	S	2	CLOSTRIDIUM BOTULINUM TOXIN

```
? p
>>>Related terms display completed...
```

```
? s r1:r10
      S9      12487  R1:R10
? ds
```

Set	Items	Description
S1	1545	'BEDSORES': 'BEDSORESOLUTIONS'
S2	1848	'BEDSORE': 'BEDSORES'
S3	17640	R1:R3
S4	22428	R1:R3
S5	31395	S1 OR S2 OR S3 OR S4
S6	8658	'BOTOX': 'BOTOX BOTULINUM TOXIN'
S7	11	'BOTOX BOTULINUM TOXIN A': 'BOTOX BOTULINUM TYPE A TOXIN'
S8	12255	'BOTULINUM TOXIN': 'BOTULINUM TOXIN --DRUG COMPARISON --CM'
S9	12487	R1:R10

```
? s s6 or s7 or s8 or s9
      8658  S6
      11    S7
```

12255 S8
 12487 S9
 S10 24410 S6 OR S7 OR S8 OR S9
 ? ds

Set	Items	Description
S1	1545	'BEDSORES': 'BEDSORESOLUTIONS'
S2	1848	'BEDSORE': 'BEDSORES'
S3	17640	R1:R3
S4	22428	R1:R3
S5	31395	S1 OR S2 OR S3 OR S4
S6	8658	'BOTOX': 'BOTOX BOTULINUM TOXIN'
S7	11	'BOTOX BOTULINUM TOXIN A': 'BOTOX BOTULINUM TYPE A TOXIN'
S8	12255	'BOTULINUM TOXIN': 'BOTULINUM TOXIN --DRUG COMPARISON --CM'
S9	12487	R1:R10
S10	24410	S6 OR S7 OR S8 OR S9

? s s5 (100n) s10
 31395 S5
 24410 S10
 S11 3 S5 (100N) S10
 ? t s11/6/all

11/6/1 (Item 1 from file: 45)
 01391469 EMCare No: 38028447
 Treatments for spasticity and pain in multiple sclerosis: A systematic
 review
 2003

11/6/2 (Item 2 from file: 45)
 01353506 EMCare No: 37296714
 Index of Suspension
 2003

11/6/3 (Item 3 from file: 45)
 00643988 EMCare No: 29405849
 Mycobacterium ulcerans disease; Buruli ulcer
 1999
 ? t s11/6,kwic/all
 >>>KWIC option is not available in file(s): 399

11/6,KWIC/1 (Item 1 from file: 45)
 DIALOG(R)File 45:(c) 2008 Elsevier B.V. All rts. reserv.

01391469 EMCare No: 38028447
 Treatments for spasticity and pain in multiple sclerosis: A systematic
 review
 2003

DESCRIPTORS:
 baclofen; tizanidine; diazepam; dantrolene; botulinum toxin; phenol;
 octreotide; misoprostol; mexiletine; methylprednisolone; steroid;
 vigabatrin; unindexed drug; tetrazepam; threonine; tricyclic antidepressant
 agent...

...ketazolam; cost effectiveness analysis; intrathecal drug administration;
 register; clinical trial; quality of life; drug capsule; decubitus;
 cost utility analysis; disease exacerbation; etiology; side effect; muscle
 weakness; muscle rigidity; mycosis; national health...

11/6,KWIC/2 (Item 2 from file: 45)
DIALOG(R)File 45:(c) 2008 Elsevier B.V. All rts. reserv.

01353506 EMCare No: 37296714
Index of Suspension
2003

DESCRIPTORS:

amikacin; rifampicin; ethambutol; clarithromycin; ciprofloxacin;
botulinum toxin; atropine; skin infection; strabismus; skin
ulcer; skin biopsy; Mycobacterium; male; human; histopathology; hearing
loss; female; disease association; clinical feature; differential...

11/6,KWIC/3 (Item 3 from file: 45)
DIALOG(R)File 45:(c) 2008 Elsevier B.V. All rts. reserv.

00643988 EMCare No: 29405849
Mycobacterium ulcerans disease; Buruli ulcer
1999

DESCRIPTORS:

rifampicin; streptomycin; clarithromycin; antibiotic agent; bacterial
toxin; dapsone; mycobacteriosis; recurrent disease; short survey; split
thickness skin graft; skin ulcer; clinical feature; debridement;
human
? t s11/9/1-2

11/9/1 (Item 1 from file: 45)
DIALOG(R)File 45:EMCare
(c) 2008 Elsevier B.V. All rts. reserv.

01391469 EMCare No: 38028447
Treatments for spasticity and pain in multiple sclerosis: A systematic
review
Beard S.; Hunn A.; Wight J.
S. Beard, School of Health/Related Research, University of Sheffield,
Sheffield United Kingdom
Health Technology Assessment (HEALTH TECHNOL. ASSESS.) (United Kingdom)
2003, 7/40 (111p)
CODEN: HTASF ISSN: 1366-5278
DOCUMENT TYPE: Journal ; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 154
RECORD TYPE: Abstract

Objectives: To identify the drug treatments currently available for the
management of spasticity and pain in multiple sclerosis (MS), and to
evaluate their clinical and cost-effectiveness. Data sources: Electronic
bibliographic databases, National Research Register, MRC Clinical Trials
Register and the US National Institutes of Health Clinical Trials Register.
Review methods: Systematic searches identified 15 interventions for the
treatment of spasticity and 15 interventions for treatment of pain. The
quality and outcomes of the studies were evaluated. Reviews of the
treatment of spasticity and pain when due to other aetiologies were also
sought. Results: There is limited evidence of the effectiveness of four
oral drugs for spasticity: baclofen, dantrolene, diazepam and tizanidine.
Tizanidine appears to be no more effective than comparator drugs such as
baclofen and has a slightly different side-effects profile. Despite claims
that it causes less muscle weakness, there was very little evidence that

tizanidine performed any better in this respect than other drugs, although it is more expensive. The findings of this review are consistent with reviews of the same treatments for spasticity derived from other aetiologies. There is good evidence that both botulinum toxin (BT) and intrathecal baclofen are effective in reducing spasticity, and both are associated with functional benefit. However, they are invasive, and substantially more expensive. None of the studies included in the review of pain were designed specifically to evaluate the alleviation of pain in patients with MS and there was no consistency regarding the use of validated outcome measures. It was suggested that, although expensive, the use of intrathecal baclofen may be associated with significant savings in hospitalisation costs in relation to bed-bound patients who are at risk of developing pressure sores, thus enhancing its cost-effectiveness. No studies of cost-effectiveness were identified in the review of pain. There is evidence, albeit limited, of the clinical effectiveness of baclofen, dantrolene, diazepam, tizanidine, intrathecal baclofen and BT and of the potential cost-effectiveness of intrathecal baclofen in the treatment of spasticity in MS. Conclusions: Many of the interventions identified are not licensed for the alleviation of pain or spasticity in MS and the lack of evidence relating to their effectiveness may also limit their widespread use. Indeed, forthcoming information relating to the use of cannabinoids in MS may result in there being better evidence of the effectiveness of new treatments than of any of the currently used drugs. It may therefore be of value to carry out double-blind randomised controlled trials of interventions used in current practice, where outcomes could include functional benefit and impact on quality of life. Further research into the development and validation of outcomes measures for pain and spasticity may also be useful, as perhaps would cost-utility studies.

Copyright 2006 Elsevier B.V., All rights reserved.

BRAND NAME/MANUFACTURER NAME: lioresal; dantrium; zanaflex; neurontin; botox; dysport; sirdalud; valium; cytotec; xylocaine

DESCRIPTORS:

*spasticity; *pain; *multiple sclerosis; *systematic review
 baclofen; tizanidine; diazepam; dantrolene; botulinum toxin; phenol;
 octreotide; misoprostol; mexiletine; methylprednisolone; steroid;
 vigabatrin; unindexed drug; tetrazepam; threonine; tricyclic antidepressant
 agent; progabide; phenytoin; cyproheptadine; clonidine; amantadine;
 bupivacaine; cannabinoid derivative; carbamazepine; botulinum toxin A;
 cannabinoid; acetazolamide; lamotrigine; lidocaine; magnesium; gabapentin;
 ketazolam; cost effectiveness analysis; intrathecal drug administration;
 register; clinical trial; quality of life; drug capsule; decubitus;
 cost utility analysis; disease exacerbation; etiology; side effect; muscle
 weakness; muscle rigidity; mycosis; national health service; nausea;
 nonhuman; obturator nerve; optic nerve disease; paresthesia; outcomes
 research; malaise; injection site; muscle hypotonia; motor coordination;
 monotherapy; meningitis; slurred speech; indigestion; infection;
 intoxication; vomiting; walking speed; wound infection; xerostomia; visual
 impairment; validation process; thalamotomy; transcutaneous nerve
 stimulation; trigeminal neuralgia; somnolence; skin bruising; sedation;
 pump; pseudotumor; stomach pain; postoperative infection; postoperative
 complication; health care cost; diarrhea; data base; concentration loss;
 clonus; catheterization; catheter infection; drug therapy; health; hospital
 patient; patient; bibliographic database; risk; clinical effectiveness;
 randomized controlled trial; disability; leg edema; impotence;
 hyperreflexia; hydrotherapy; human; hospitalization; health economics;
 disease severity; drug efficacy; erectile dysfunction; exercise; fatigue;
 gait disorder; headache; drug cost; drug blood level; drowsiness; dose
 calculation; dizziness

11/9/2 (Item 2 from file: 45)
DIALOG(R)File 45:EMCare
(c) 2008 Elsevier B.V. All rts. reserv.

01353506 EMCare No: 37296714
Index of Suspension
Scott D.A.; Young P.C.; Browning J.C.; Miller T.D.; Metry D.W.; Narchi H.
Dr. D.A. Scott, University of Utah, Salt Lake City, UT United States
Pediatrics in Review (PEDIATR. REV.) (United States) 2003, 24/11
(387-393)
CODEN: PDREF ISSN: 0191-9601
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH
RECORD TYPE: Citation
Copyright 2006 Elsevier B.V., All rights reserved.

DESCRIPTORS:
amikacin; rifampicin; ethambutol; clarithromycin; ciprofloxacin;
botulinum toxin; atropine; skin infection; strabismus; skin
ulcer; skin biopsy; Mycobacterium; male; human; histopathology; hearing
loss; female; disease association; clinical feature; differential diagnosis
; diagnostic test; child; case report